Claim Amendments

1-9 (canceled)

10 (currently amended): A method of increasing glucose dependent insulin secretion in a pancreatic β-cell in a mammal, where the mammal is in need of increased glucose dependent insulin secretion, the method comprising administering an effective amount of a selective inhibitor of phosphodiesterase 1C to the mammal.

11 (previously presented): The method of claim 10, wherein the inhibitor is an isobutylmethylxanthine with substitutions consisting of a moiety at positions 2 (R1) and 8 (R2) independently selected from the group consisting of an alkyl (C_1 to C_3), a flouroalkyl (F_1 to F_3), a chloroalkyl (Cl_1 to Cl_3), an aryl (C_5 to C_6), a fluoroaryl (F_1 to F_2), and a chloroaryl (Cl_1 to Cl_2).

12 (cancelled)

13 (currently amended): The method of claim 10, wherein the inhibitor is selected from the group consisting of zaprinast, 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX), ~~vinpocetine, rolipram, milrinone,~~ and combinations thereof.

14 (previously added): The method of claim 13, wherein the inhibitor is zaprinast.

15 (previously added): The method of claim 13, wherein the inhibitor is 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX).

16 (previously added): The method of claim 10, wherein the mammal is a human.

17 (previously added): The method of claim 10, wherein the inhibitor is administered in an amount effective to regulate blood sugar levels in the mammal.

18 (previously added): The method of claim 10, wherein the inhibitor is administered orally.

19 (previously added): The method of claim 10, wherein the inhibitor is administered in combination with an anti-diabetic agent selected from the group consisting of insulin, a sulfonylurea, and a biguanide.